News About: Pharm. Industry
Domestic pharmaceutical companies tighten Compliance Program due to multinational companies
Although domestic pharmaceutical companies have recently tightened Compliance Program in series, one of their reasons for the phenomenon was known to establish partnership with multinational pharmaceutical companies.
...
A series of WHO PQ triggers vaccines development of domestic pharmaceutical companies
A series of the WHO PQs by domestic pharmaceutical and biopharmaceutical companies are expected to accelerate the domestic vaccine development.
A pentavalent complex vaccine developed by LG Life Sciences for the firs...
GSK’s HIV treatment, ‘Triumeq’ lands in approximately s30 major hospitalsGSK(CEO Yoo-seok Hong) invigorates ‘Triumeq’ prescriptions.
According to GSK, ‘Triumeq(dolutegravir 50mg, abacavir 600mg, lamivudine 300mg),’ a complex HIV treatment which cont...
|
Samsung’s partner, Biogen files patent infringement trial against Celltrion
Biogen Idec, the patentee of Mabthera(foreign name: Rituxan), applied for a judgment for the patent infringement against Celltrion.
Biogen is not only the second largest shareholder holding 9.7% of the entire Samsung...
What are Celltrion’s future schedule after the entry to the U.S. market?The future direction of ‘Remsima,’ a Celltrion’s biosimilar antibody, has attracted attention as receiving the approval recommendation from the U.S. FDA Arthritis Advisory Commi...
|
Raised status of domestic anticancer drugs
‘Supect(radotinib)’ developed by Ilyang Pharmaceutical emerged in the leukemia treatment market which used to be occupied only by multinational companies. Anticancer treatments are no longer multinational companies’ e...
Pharmaceutical industry’s KRW 1 trillion era competing for global pharmaceuticals
An era of KRW 1 trillion pharmaceutical sales has begun.
Last year, there were 3 pharmaceutical companies recording over KRW 1 trillion sales: Hanmi Pharm for KRW 1.3175 trillion, Green Cross for KRW 1.0478 trillion ...
While are biopharmaceutical companies after Hanmi Pharm?While the biopharmaceutical industry has attracted high interests as the Hanmi Pharm’s technology transfers have been on everyone’s lips, a report was out from the securities in...
|
Domestic pharmaceutical companies develop salt-modified drugs of Viread in series
Dong-A ST, Chong Kun Dang, CJ HealthCare and JW Pharmaceutical are developing incrementally modified drugs of Viread(generic name: tenofovir), a chronic hepatitis B treatment.
The pharmaceutical companies have field ...
Dong-A ST wants competing product, Forsteo, to receive insurance benefit for its products, TeriboneDong-A ST has paid attention to the availability of the health insurance benefit of ‘Forsteo,’ an osteoporosis treatment which has not received the insurance benefit already for...
|
